




AAC-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics


October 11–15, 2023 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients.

Relationships are abbreviated as follows: E, Employment; FO, Fiduciary Officer; IC, Independent Contractor; S, Stock; SO, Stock Option; OS, Other Securities; OBO, Other Business Ownership; GC, Grant/Contract; T, Travel; GI, Gift; P, Patent; TM, Trademark, C, Copyright; OIP, Other Intellectual Property; O, Other

Last Name	First Name	All Relationships	Type	Role
Alemdehy	Farshid	Genmab B.V., Genmab B.V., Genmab B.V.	E, SO, SO	Speaker
Alici	Evren	Vycellix	S	Speaker
Alix-Panabières	Catherine	MENARINI SILICON BIOSYSTEMS, INC.	GC	Speaker
Al-Lazikani	Bissan	Exscientia PLC, Exscientia PLC, AstraZeneca, Astex Pharmaceuticals, Exscientia PLC GSK, Astelas Pharma, AstraZeneca, Novodordisk, Cancer Research UK Commercial Partnerships	S, SO, GC, IC, IC, IC, IC, IC, IC	Speaker
Amaria	Rodabe	Novartis, Onkure, Obsidian Therapeutics, Bristol Myers Squibb Company, F. Hoffmann-La Roche	IC, IC, IC, IC, IC	Speaker
André	Fabrice	AstraZeneca, Pfizer Foundation, Eli Lilly and Company, Hoffmann-La Roche Limited, Novartis	GC, GC, GC, GC, GC	Speaker
Annunziata	Christina	No Relationships		Program Committee
Arthur	Ronald	No Relationships		Staff
Aurigemma	Rosemarie	No Relationships		Program Committee
Banerji	Udai	Verastem, Inc., Carrick Therapeutics, Chugai Pharmaceutical, Institute of Cancer Research, Carrick Therapeutics	GC, GC, GC, E, IC	Program Committee
Basu	Bristi	Genmab	IC	Program Committee




AAC-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 11–15, 2023 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Creelan	Benjamin	instil Bio Inc, Regeneron Pharmaceuticals, Inc., , Cancer Research Institute, AstraZeneca, American Association for Cancer Research, Achilles Therapeutics, plc, Stand Up To Cancer, E.R. Squibb & Sons, L.L.C., Iovance Biotherapeutics inc, Clinigen Inc, F. Hoffmann-La Roche AG, H. Lee Moffitt Cancer Center and Research Institute	IC, IC, P, GC, IC, GC, IC, GC, IC, IC, IC, IC, E	Speaker
Curigliano	Giuseppe	SANOFI US SERVICES INC., Daiichi Sankyo Company, PFIZER PHARMA GMBH, Associazione Italiana di Oncologia Medica, Merck, Novartis, Bristol Myers Squibb Company, Seagen Inc., Gilead Sciences Inc, Annals of Oncology (European Society for Medical Oncology), AstraZeneca, Eli Lilly and Company, F. Hoffmann-La Roche	IC, IC, IC, FO, GC, IC, IC, IC, IC, FO, IC, IC, IC	Program Committee
Dagogo-Jack	Ibiayi	AstraZeneca, Boehringer Ingelheim, Bayer, BostonGene, Bristol Myers Squibb, Catalyst, Foundation Medicine, Genentech, Janssen, Merus, Novocure, Pfizer, Sanofi-Genzyme, Syros, Xcovery, research support from Array, Genentech, Novartis, Pfizer, and Guardant Health.	IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, GC, GC, GC, GC, GC	Program Committee
De Miguel	Maria	No Relationships		Speaker
De Vries	E.G. Elisabeth	NSABP (National Surgical Adjuvant Breast and Bowel Project), Daiichi Sankyo Inc., G1 Therapeutics, CytomX, Bayer, Roche, Synthron, Genentech, ESMO (European Society for Medical Oncology), World Health Organization, Regeneron Pharmaceuticals, Inc., Crescendo Biologics, Crescendo Biologics, Amgen, ESMO (European Society for Medical Oncology), RECIST (Response Evaluation Criteria in Solid Tumours), Servier	IC, IC, GC, GC, GC, GC, GC, GC, IC, IC, GC, IC, GC, GC, IC, IC, GC	Program Committee, Speaker
DeMong	Duane	Merck	E	Speaker
Dijkstra	Krijn	Achilles Therapeutics UK Ltd	IC	Speaker
Doroshov	James	No Relationships		Program Committee, Speaker




AAC-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 11–15, 2023 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Dumbrava	Ecaterina	Bellicum Pharmaceuticals, Aileron Therapeutics, Immunocore LTD, BOLT Therapeutics, Seagen Inc., Aprea Therapeutics, Immunomedics, Inc., NCI, PMV Pharma, Unum Therapeutics, Mersana, Triumvira, Compugen Ltd, Amgen, Mereo BioPharma 5 Inc, Bayer HealthCare Pharmaceuticals Inc., Astex Therapeutics, Catamaran Bio, Sanofi, TRACON Pharmaceuticals Inc	GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, IC, GC, GC, GC, GC, GC, IC, GC, GC	Speaker
Ebert	Benjamin	Skyhawk Therapeutics, Deerfield, Neomorph Therapeutics, Calico, Exo Therapeutics, Novartis, TenSixteen Bio	IC, GC, IC, GC, IC, GC, IC	Speaker
Elimova	Elena	Bristol-Myers Squibb, Novartis, Amgen, BeiGene, Ltd., Astellas Pharma, Viracta Tx, AstraZeneca, Zymeworks, Merck, Zymeworks, Adaptimmune LLC, Bristol-Myers Squibb	GC, IC, IC, IC, IC, IC, IC, IC, E, GC, IC, IC	Speaker
Eskra	Jillian	No Relationships		Speaker
Garnett	Mathew	Astex Pharmaceuticals, MosaicTherapeutics, UKRI: United Kingdom Research and Innovation, MosaicTherapeutics, Open Targets, GlaxoSmithKline, MosaicTherapeutics	GC, OBO, GC, GC, GC, GC, IC	Speaker
Garralda	Elena	Novartis, Thermo Fisher Scientific, MabDiscovery, Eli Lilly and Company, Neomed Therapeutics, Alkermes, Inc., Anaveon, F-star Therapeutics, Novartis, F. Hoffmann-La Roche, Roche, Taiho Oncology, Inc., Thermo Fisher Scientific, Hengrui, Seattle Genetics, Bristol-Myers Squibb, BeiGene USA, Inc., AstraZeneca, MSD, Janssen Global Services, LLC, Ellipses Pharma, SANOFI US SERVICES INC., Boehringer Ingelheim	IC, GC, IC, IC, IC, IC, IC, IC, GC, GC, IC, GC, IC, IC, IC, IC, GC, GC, IC, IC, IC, IC, IC	Program Committee, Speaker
Garrido-Laguna	Ignacio	No Relationships		Program Committee
Gill	Adrian	Revolution Medicines	E	Program Committee
Gong	Lanqi	No Relationships		Speaker
Greenberg	Philip	Juno Therapeutics, FibroGen, Lonza, Affini-T, Lonza, Bristol Myers Squibb Company, Elpiscience, Rapt, Affini-T, Elpiscience, Immunoscapes, Bristol Myers Squibb Company, Adaptive Biotechnologies Corporation, Bristol Myers Squibb Company, Nextech, Celsius, Affini-T, Rapt, Nextech, Affini-T, Bristol Myers Squibb Company, Affini-T, Catalio, Catalio, Earli, Affini-T, Earli, Metagenomi, Bristol Myers Squibb Company, Immatics, Lonza, Metagenomi, Immunoscapes, Affini-T, Bristol Myers Squibb Company, Lonza	P, IC, P, P, P, P, IC, SO, GC, SO, IC, P, P, P, S, SO, IC, IC, IC, P, P, P, IC, SO, S, S, IC, S, P, P, P, IC, S, P, P, GC	Program Committee




AAC-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 11–15, 2023 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Im	Seock-Am	AstraZeneca, Boryung Pharm, Daewoong Pharm, Eisai, Daiichi-Sankyo, Roche, Pfizer, AstraZeneca, Bertis, Eisai, Daichi-Sankyo, Lilly, MSD, Novartis, Roche, Pfizer	GC, GC, GC, GC, GC, GC, GC, IC, IC, IC, IC, IC, IC, IC, IC, IC	Program Committee
Ishihara	Jun	ArrowImmune Inc, Imperial College London, , Libo pharma	S, E, P, IC	Speaker
Ivy	S. Percy	No Relationships		Program Committee, Speaker
Janku	Filip	Monte Rosa Therapeutics, Monte Rosa Therapeutics, Monte Rosa Therapeutics	E, SO, S	Program Committee
JAnne	Pasi	Novartis, AbbVie, Merus, Accutar Biotech, Silicon Therapeutics, Biocartis, Pfizer, Bayer, Allorion Therapeutics, Voronoi, Syndax, Eli Lilly and Company, SANOFI PASTEUR BIOLOGICS LLC, Nuvalent, Monte Rosa Therapeutics, Transcenta, Frontier Medicines, Mirati Therapeutics, Hongyun Biotechnology, Daiichi Sankyo Company, Esai, Boehringer Ingelheim, F. Hoffmann-La Roche, Takeda Oncology, Lab Corp, SFJPharmaceuticals, AstraZeneca, Scorpion Therapeutics	IC, P, IC, IC, IC	Speaker
Jiang	Peng	Patent	P	Speaker
Jorgensen	Claus	AstraZeneca, Revolutions Medicine	GC, GC	Speaker
Kaelin	William	Iconovir Bio, Casdin Capital, Eli Lilly and Company, Nextech Invest, LifeMine Therapeutics, FibroGen, Cedilla, Circle Pharma, Merck, Eli Lilly and Company, Tango Therapeutics	IC, IC, FO, IC, FO, IC, IC, IC, OIP, FO, IC	Speaker
Knee	Deborah	Novartis	E	Speaker
Kuchroo	Vijay	PerkinElmer, Biocon, Trishula, Novartis Sabatolimab, Bicara, Janssen Global Services, LLC, Tr1X, Viela Bio, Syngene, Biolegend, EMD Serono, Inc., AZTherapies, Larkspur, Senda, Equillium, GlaxoSmithKline, LLC., Tizona, Pfizer, Tizona, Surface Oncology, Bicara, Celsius, ImmuneOncia, Larkspur, Werewolf Tx, Alpine Immune Science, Incyte Corporation, Implicit Bioscience, Elpiscience, Celsius, Larkspur, Vividion, Servier Pharmaceuticals LLC, Trishula, EcoR1 Capital, Celsius, Cell Signaling Technology, Almirall LLC, Equillium, Elpiscience, Compass, iTeos, Syngene, Reistone Biopharma, Sanofi/Genzyme	S, FO, S, IC, FO, IC, IC, IC, FO, IC, IC, IC, S, IC, IC, IC, OBO, IC, IC, IC, OBO, IC, IC, IC, IC, IC, S, S, OBO, IC, IC, OBO, IC, OBO, IC, IC, S, IC, S, IC, S, IC, IC	Speaker




AAC-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 11–15, 2023 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Lacombe	Denis	No Relationships		Program Committee
Le	Xiuning	Daiichi Sankyo Company, BlossomHill, Janssen Biotech, Merck KGaA, Blueprint Medicines Corporation, AbbVie, Novartis, Regeneron Pharmaceuticals, Inc., Boehringer Ingelheim, Spectrum Pharmaceuticals Inc., AstraZeneca, Eli Lilly and Company	IC, SO, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC	Speaker
Le Tourneau	Christophe	Seagen Inc., Merck Sharp & Dohme Corporation, F. Hoffmann-La Roche, Seattle Genetics, Incyte Corporation, EMD Serono	IC, IC, IC, IC, IC, IC	Speaker
Lin	Jessica	Regeneron Pharmaceuticals, Bayer, Blueprint Medicines Corporation, Nuvalent, Takeda Oncology, Ellipses Pharma, Nuvalent, Turning Point Therapeutics, Mirati Therapeutics, Relay Therapeutics, Elevation Oncology, Hengrui Therapeutics, Novartis, Pfizer, Elevation Oncology, Claim Therapeutics, F. Hoffmann-La Roche, Turning Point Therapeutics, Novartis, AnHeart Therapeutics, Linnaeus Therapeutics, Neon Therapeutics, Genentech, Hyku BioSciences, Bayer, C4 Therapeutics	IC, GC, IC, GC, IC, IC, IC, IC, IC, GC, IC, GC, IC, IC, GC, IC, GC, GC, GC, GC, IC, GC, GC, IC, IC, IC, IC	Speaker
Lopez	Juanita	Roche-Genentech, Basilea, Astex, Merck, GSK, Eisai, Seagen, Immunocore, Bicycle Tx, AstraZeneca, Genmab, Bayer, Janssen, Gilead, Anaveon, Affimed, Appollomics, Avacta, Byondis, Chugai, CellCentric, Daiichi, Iteos, Merck-Serono, REDX, Amgen, Basilea, Roche-Genentech, Ellipses, Eisai, Pierre-Faber, Genmab	GC, IC, IC, IC, IC, IC, IC	Speaker
LoRusso	Patricia	Compass BADX, BAKX Therapeutics, Roivant Sciences, Kineta, STCube Pharmaceuticals, imCheck, Qualigen, Kyowa Kirin Pharmaceutical Development, Inc, ABL Bio, Seagen Inc., Mersana Therapeutics, Actuate Therapeutics, Stemline Therapeutics Inc., Relay Therapeutics, Mekanist, Zentalis Pharmaceuticals, I-Mab, QED Therapeutics, Molecular Templates, Scenic Biotech, NeuroTrials	IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC	Program Committee, Speaker
Luke	Jason	No Relationships		Program Committee, Speaker
Madej	Mariusz	Crown Bioscience Netherlands B.V.	E	Speaker




AAC-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 11–15, 2023 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Newman	Aaron	Patent	P	Speaker
Ngoi	Natalie	AstraZeneca, AstraZeneca, PFIZER CANADA INC	IC, IC, IC	Program Committee
Nomura	Daniel	Frontier Medicines, Vicinitas Therapeutics, Photys Therapeutics, Apertor Therapeutics, a16z, Droia Ventures, Vicinitas Therapeutics, Oerth Bio, Frontier Medicines	IC, FO, S, IC, IC, IC, S, IC, S	Speaker
O'Keefe	Barry	No Relationships		Speaker
Ott	Patrick	Evaxion, Merck Sharp & Dohme Corporation, Agenus, F. Hoffmann-La Roche, Bristol Myers Squibb Company	IC, IC, GC, GC, IC	Speaker
Pantel	Klaus	Sanofi, Novartis Pharma AG, MENARINI SILION BIOSYSTEMS, INC.	IC, IC, IC	Speaker
Parchment	Ralph	No Relationships		Program Committee
Parikh	Aparna	Inivata, Parithera, Up To Date, Taiho Oncology, Inc., Value Analytics Lab, AstraZeneca, Massachusetts General Hospital, AbbVie, Foundation Medicine, Inc., Xgenomes, C2i Genomics, Eli Lilly, Pfizer, Saga, Illumina, Checkmate, Biofidelity, Scare, CVS, Delcath, Bayer, Seagen Inc.	IC, OBO, IC, IC, IC, IC, E, IC, IC, OBO, OBO, IC, IC, IC, IC, IC, IC, IC, IC, IC, IC	Speaker
Patricelli	Matthew	Vividion Therapeutics	E	Speaker
Peng	Li	Palleon Pharmaceuticals	E	Speaker
Perera	Rushika	Lime Therapeutics	SO	Speaker
Post	Dean	No Relationships		Staff
Postel-Vinay	Sophie	IMCore (Roche), Novartis, AstraZeneca, AstraZeneca, GlaxoSmithKline, Daiichi Sankyo Company, Clovis Oncology, Inc., Amgen	GC, IC, GC, IC, IC, IC, IC, IC	Program Committee
Punekar	Salman	No Relationships		Speaker
Rapisarda	Annamaria	No Relationships		Speaker
Rasco	Drew	Merck, Arcus Biosciences, Compugen USA, Inc., GlaxoSmithKline, LLC.	IC, IC, IC, IC	Speaker




AAC-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 11–15, 2023 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Rodón	Jordi	CytomX, BioAtla, Nuvation, Envision Pharma, Vall d'Hebron Institute of Oncology/ Cancer Core Europe, GenMab, European Society for Medical Oncology, Boxer Capital, LLC, Hummingbird, Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social, GlaxoSmithKline, Amgen, Aadi Bioscience, Loxo Oncology, Kelun-Biotech, Chinese University of Hong Kong, Merus, Yingli, IONCTURA, Curis, Tang Advisors, LLC, Ellipses Pharma, Pfizer, Cullgen, ForeBio, Columbus Venture Partners, Merus, Monte Rosa Therapeutics, Bicycle Therapeutics, Sardona Therapeutics, Roche Pharmaceuticals, Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social, Blueprint Medicines Corporation, Takeda-Millennium, Merck Sharp & Dohme, Mirati, BioMed Valley Discoveries, Pfizer, Avoro Capital Advisors, MacroGenics, Clarion Healthcare, Cellestia, Aadi Bioscience, Black Diamond, Taiho, Spectrum Pharmaceuticals, Bayer, Novartis, Symphogen, Tango Therapeutics, Ideaya, Debiopharm, Oncology One, Hutchinson Medipharma, Linnaeus Therapeutics, Deciphera Pharmaceuticals Inc.	GC, GC, GC, IC, GC, GC, IC, IC, GC, IC, GC, GC, IC, GC, GC, IC, IC, GC, IC, GC, IC, GC, IC, GC, IC, GC, GC, GC, GC, GC, IC, IC, IC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC, GC	Speaker
Romee	Rizwan	InnDura Therapeutics, Parker Institute, Skyline Therapeutics, Crispr Therapeutics, Skyline Therapeutics, Glycostem, xNK therapeutics	OBO, GC, P, GC, GC, IC, IC	Speaker
Roschewski	Mark	No Relationships		Program Committee
Ruppin	Eytan	No Relationships		Program Committee, Speaker
Ryan	Aideen	Patent	P	Speaker
Schalper	Kurt	F. Hoffmann-La Roche, OnCusp Therapeutics, Surface Oncology, Merck Sharp and Dohme, AstraZeneca, CDR life, EMD Serono, Navigate Biopharma, AstraZeneca, Sensei Therapeutics, Parthenon Therapeutics, Takeda Oncology, Ariagen, Repertoire Therapeutics, Boehringer Ingelheim, Genmab, Eli Lilly and Company, Akoya Biosciences, Merck Sharp and Dohme, Moderna Inc, Agenus, Shattuck Labs, TESARO, Inc., Ribon Therapeutics, Clinica Alemana de Santiago, Molecular Templates, Takeda Oncology, Bristol-Myers Squibb, Bristol-Myers Squibb	IC, IC, GC, IC, IC, IC, IC, GC, GC, IC, IC, IC, IC, IC, GC, IC, GC, GC, GC, GC, IC, IC, GC, GC, IC, IC, GC, GC, IC	Program Committee




AAC-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 11–15, 2023 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Spira	Alexander	Novartis, Bayer, Array BioPharma, Incyte Corporation, Nalo Therapeutics, black diamond therapeutics, Gritstone Bio, Gritstone Oncology, Amgen, Mersana, Novartis, black diamond therapeutics, Jazz Pharmaceuticals, CytomX Therapeutics, Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Merck, Mirati Therapeutics, Arrivent BioPharma, Blueprint Medicines Corporation, Eli Lilly and Company, AstraZeneca/MedImmune, Merck, Medikine, Janssen Research and Development, black diamond therapeutics, Sanofi, Takeda, Bristol-Myers Squibb, Takeda, Scorpion Therapeutics, Regeneron Pharmaceuticals, Daiichi Sankyo/AstraZeneca, Janssen Oncology	IC, G, IC, IC, GC, GC, IC, IC, IC, IC, G, GC, IC, G, G, IC, IC, G, IC, GC, IC, S, G, IC, GC, IC, IC, IC, IC, G, G, GC, IC, IC, G	Speaker
Srinivasan	Ramaprasad	Novartis, Nikang Therapeutics, Genentech USA, Inc., Merck, Calithera Biosciences, Peloton, Inc, Calithera Biosciences	GC, GC, GC, GC, IC, IC, GC	Program Committee
Stagg	John	No Relationships		Speaker
Stark	Jessica	Valora Therapeutics, Rondo Therapeutics, , Rondo Therapeutics	S, S, P, IC	Speaker
Stegmaier	Kimberly	AstraZeneca, Auron Therapeutics, Bristol-Myers Squibb, Auron Therapeutics, Novartis, Auron Therapeutics, Kronos Bio	IC, SO, IC, IC, GC, IC, GC	Speaker
Stott	Shannon	Patent, Streck, Inc., Patent	P, IC, P	Speaker
Subbiah	Vivek	Incyte Corporation, Exelixis Inc., Idera Pharma, The University of Texas MD Anderson Cancer Center, Agensys, GlaxoSmithKline, LLC., American Society of Clinical Oncology, National Cancer Institute, Helsinn Healthcare SA, MedImmune, LLC, Incyte Corporation, Takeda Oncology, National Comprehensive Cancer Network, Bayer HealthCare Pharmaceuticals Inc., LOXO Oncology, Boston Biomedical, Medscape, FUJIFILM Medical Systems USA, Inc., Pharmamar, Amgen Inc., Berghealth, D3, Inhibrx, Incyte Corporation, Dagonflytherapeutics, Northwest Biotherapeutics, Genentech USA, Inc., Blueprint medicines, AbbVie, Inc., European society of medical oncology, Pfizer, Novartis Pharma, Eli Lilly and Company	IC, GC, GC, E, GC, GC, IC, GC, IC, GC, GC, GC, GC, GC, GC, IC, GC, GC, GC, GC, GC, IC, GC, GC, GC, GC, IC, GC, GC, GC, GC, IC, GC, GC, GC	Speaker
Symeonides	Stefan	Ipsen Biopharm Limited, Merck, BioNTech, EUSA	IC, IC, IC, IC	Program Committee



AAC-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 11–15, 2023 | Boston, MA

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Last Name	First Name	All Relationships	Type	Role
Workman	Paul	CHARM Therapeutics, Merck KGaA, AstraZeneca, Merck KGaA, Alterome Therapeutics, Nuvectis Pharma, CHARM Therapeutics, Astex Pharmaceuticals, Vividion Therapeutics, Nuvectis Pharma, STORM Therapeutics, Merck KGaA, Nuvectis Pharma, STORM Therapeutics, Black Diamond Therapeutics, STORM Therapeutics, Alterome Therapeutics, Nuvectis Pharma, Astex Pharmaceuticals, Chemical Probes Portal, Epicombi Therapeutics, Alterome Therapeutics, NextechInvest, Epicombi Therapeutics, STORM Therapeutics, NextechInvest, Black Diamond Therapeutics, CV6 Therapeutics, Astex Pharmaceuticals, STORM Therapeutics	IC, GC, IC, P, IC, P, SO, P, IC, GC, IC, IC, IC, SO, IC, FO, IC, SO, IC, IC, IC, SO, SO, SO, SO, IC, SO, IC, GC, IC	Speaker
Yamamoto	Noboru	Boehringer Ingelheim, Merck, Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd.	IC, IC, IC, IC, IC	Program Committee
Yang	James	Patent	P	Program Committee, Speaker
Yap	Timothy	No Relationships		Program Committee, Speaker
Zhang	Tong	Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc.	S, SO, E	Speaker
Zou	Lee	Pfizer, Sirrona Therapeutics, Bristol Myers Squibb Company	GC, SO, GC	Speaker

All of the relevant financial relationships listed for these individuals have been mitigated.